DURHAM, N.C., Nov. 24, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis® technology platform, today announced the company has been honored with a 2014 Red Herring North America Top 100 award.
“We are delighted to be included on this list of North American companies developing truly revolutionary technologies founded on business models that have the potential to disrupt our respective markets,” said Jeff Abbey, president and CEO of Argos. “It is an exciting time for Argos and the next few years will include important milestones as we continue to advance our patient-specific immunotherapies based on the Arcelis® technology platform through late stage clinical research.”
Over the past two decades the Red Herring Top 100 awards have highlighted companies developing innovative technologies and business models. The Red Herring editorial team selects technology and life science companies based on criteria including level of specialty, social contribution, and revenues and growth rate.
“Aside from making potentially life-altering technology, Argos Therapeutics has also developed an efficient way to manufacture the treatments,” noted the Red Herring editorial team.
The 2014 Top 100 winners in North America were announced at the Red Herring Global 2014 forum held in Los Angeles from November 18-20, 2014.
About the Arcelis® Technology Platform
Arcelis® is a fully personalized immunotherapy technology that captures mutated and variant antigens that are specific to each patient’s disease. It is designed to overcome immunosuppression by producing a durable memory T-cell response without adjuvants that may be associated with toxicity. The technology is potentially applicable to a wide range of different cancers and infectious diseases and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized immunotherapies. The Arcelis® process uses only a small tumor or blood sample and the patient’s own dendritic cells, which are collected and optimized following a single leukapheresis procedure. The proprietary process uses RNA isolated from the patient’s disease sample to program dendritic cells to target disease antigens. The activated, antigen-loaded dendritic cells are then formulated into the patient’s plasma and administered via intradermal injection.
About Argos Therapeutics
Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis® technology platform. Argos’ most advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). The Company is also developing a second Arcelis®-based product candidate, AGS-004, for the treatment of HIV, currently being evaluated in a phase 2 clinical trial in combination with a latency reversing drug for HIV eradication in adult patients. For more information about Argos Therapeutics, visit www.argostherapeutics.com.
Forward Looking Statements
Any statements in this press release about Argos’ future expectations, plans and prospects, including statements about Argos and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including whether Argos’ cash resources will be sufficient to fund our continuing operations for the period anticipated; whether results obtained in clinical trials will be indicative of results obtained in future clinical trials; whether Argos’ product candidates will advance through the clinical trial process on a timely basis and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if product candidates obtains approval, they will be successfully distributed and marketed; and other factors discussed in the “Risk Factors” section of Argos’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2014 which is on file with the SEC. In addition, the forward-looking statements included in this press release represent the Argos’ views as of November 24, 2014. Argos anticipates that subsequent events and developments will cause Argos’ views to change. However, while Argos may elect to update these forward-looking statements at some point in the future, Argos specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Argos’ views as of any date subsequent to November 24, 2014.
CONTACT: Media contact: Adam Daley Berry & Company Public Relations 212-253-8881 adaley@berrypr.com Investor contact: Angeli Kolhatkar Burns McClellan akolhatkar@burnsmc.com 212-213-0006
Help employers find you! Check out all the jobs and post your resume.
